• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Director Shan Hua was granted 60,000 shares, increasing direct ownership by 83% to 132,386 units (SEC Form 4)

    6/4/25 6:34:33 PM ET
    $CERS
    EDP Services
    Technology
    Get the next $CERS alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Shan Hua

    (Last) (First) (Middle)
    C/O CERUS CORPORATION
    1220 CONCORD AVENUE SUITE 600

    (Street)
    CONCORD CA 94520

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    CERUS CORP [ CERS ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/03/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 06/03/2025 A 60,000(1) A $0 132,386 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Represents RSUs granted pursuant to the Issuer's 2024 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of the first anniversary of the date of grant or the day prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date.
    Hua Shan by Chrystal N. Jensen, attorney-in-fact 06/04/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CERS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CERS

    DatePrice TargetRatingAnalyst
    4/12/2024$5.00Buy
    Craig Hallum
    1/20/2023Buy → Neutral
    BTIG Research
    1/17/2023$3.75Overweight → Equal-Weight
    Stephens
    More analyst ratings

    $CERS
    Financials

    Live finance-specific insights

    See more
    • Cerus Corporation Announces First Quarter 2025 Financial Results

      First quarter 2025 Product Revenue of $43.2 Million, Up 13% Over Prior Year Reiterating Full-Year 2025 Product Revenue Guidance Range of $194 - $200 Million First Quarter 2025 Total Revenue of $48.9 Million Including Government Contract Revenue of $5.6 Million Conference Call Today at 4:30 pm ET Cerus Corporation (NASDAQ:CERS) announced today financial results for the first quarter ended March 31, 2025, and provided a business update. "We are off to a strong start in 2025, executing against our stated goals and making meaningful progress in advancing Cerus' mission to transform the safety and availability of transfused blood components," said William "Obi" Greenman, Cerus' president an

      5/1/25 4:00:00 PM ET
      $CERS
      EDP Services
      Technology
    • Cerus Corporation to Release First Quarter 2025 Financial Results on May 1, 2025

      Cerus Corporation (NASDAQ:CERS) announced today that its first quarter 2025 financial results will be released on Thursday, May 1, 2025, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Participants may register for the call here. While not required, interested participants are encouraged to join 10 minutes prior to the start of the event. A replay wi

      4/17/25 8:30:00 AM ET
      $CERS
      EDP Services
      Technology
    • Cerus Corporation Announces Full-Year and Fourth Quarter 2024 Financial Results

      Full-Year and Fourth Quarter 2024 Product Revenues Increased 15% and 9%, respectively, from Prior Year Periods Fourth straight quarter of positive operating cash flows Reiterating Full-Year 2025 Product Revenue Guidance Range of $194 – $200 million Cerus Corporation (NASDAQ:CERS) today announced financial results for its full year and fourth quarter ended December 31, 2024. Recent highlights include: Total revenue for full-year 2024 and fourth quarter 2024 was comprised of (in thousands, except %): Three Months Ended           Twelve Months Ended         December 31,   Change   December 31,   Change   Unaudited  

      2/20/25 4:00:00 PM ET
      $CERS
      EDP Services
      Technology

    $CERS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cerus Corporation to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

      Cerus Corporation (NASDAQ:CERS) announced today that members of the management team are scheduled to present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 in Miami, Florida, on Wednesday, June 11, 2025, at 8:40 a.m. Eastern Time. A live webcast of the presentation can be accessed via the Events & Presentation section of Cerus' Investor Relations website at ir.cerus.com. A replay of the webcast will be available on Cerus Investor Relations website shortly after the event for 30 days. ABOUT CERUS Cerus Corporation is dedicated solely to safeguarding the world's blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, Ca

      6/3/25 4:30:00 PM ET
      $CERS
      EDP Services
      Technology
    • Cerus Corporation Presents Clinical Data for INTERCEPT Blood System at the 35th Regional International Society of Blood Transfusion Congress in Milan

      Presentations and abstracts showcase the broad applicability and expected benefits of the INTERCEPT Blood System for platelets, plasma, IFC, and red blood cells Cerus Corporation (NASDAQ:CERS) today announced it will showcase the latest INTERCEPT Blood System clinical data at the 35th Regional International Society of Blood Transfusion (ISBT) Congress being held May 31 to June 4, 2025, in Milan. "The breadth of data being presented this year underscores the broad applicability of the INTERCEPT system for platelets, plasma, and cryoprecipitated fibrinogen complex as well as the potential benefit for red blood cells," said Richard J. Benjamin, Cerus' chief medical officer. "Importantly, w

      5/29/25 8:30:00 AM ET
      $CERS
      EDP Services
      Technology
    • Cerus Corporation Announces Multiple In-Country Regulatory Approvals for INT200 – Next-Generation INTERCEPT Illumination Device

      France and Switzerland approve INT200 for use with the INTERCEPT Blood System for Platelets and Plasma Cerus Corporation (NASDAQ:CERS) announced today two in-country regulatory approvals for INT200, one by the French National Agency for Medicines and Health Product Safety (ANSM) and the other by the Swiss Agency for Therapeutic Products (Swissmedic). The INT200, the Company's next generation LED-based illumination device, was developed as the new foundational platform for the INTERCEPT Blood System, with input and feedback from global customers to enhance daily blood center operations. The contemporary vertical configuration is designed to improve workflow and ergonomics while freeing u

      5/28/25 8:30:00 AM ET
      $CERS
      EDP Services
      Technology

    $CERS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Witney Frank was granted 60,000 shares, increasing direct ownership by 27% to 280,059 units (SEC Form 4)

      4 - CERUS CORP (0001020214) (Issuer)

      6/4/25 6:53:35 PM ET
      $CERS
      EDP Services
      Technology
    • Director Moore Timothy L. was granted 60,000 shares, increasing direct ownership by 41% to 205,073 units (SEC Form 4)

      4 - CERUS CORP (0001020214) (Issuer)

      6/4/25 6:48:52 PM ET
      $CERS
      EDP Services
      Technology
    • Director Swisher Daniel N Jr was granted 60,000 shares, increasing direct ownership by 41% to 207,045 units (SEC Form 4)

      4 - CERUS CORP (0001020214) (Issuer)

      6/4/25 6:44:28 PM ET
      $CERS
      EDP Services
      Technology

    $CERS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Gregory Dean A. bought $2,932 worth of shares (1,725 units at $1.70), increasing direct ownership by 3% to 61,725 units (SEC Form 4)

      4 - CERUS CORP (0001020214) (Issuer)

      1/2/25 5:46:11 PM ET
      $CERS
      EDP Services
      Technology
    • Shan Hua bought $4,975 worth of shares (2,500 units at $1.99), increasing direct ownership by 8% to 32,386 units (SEC Form 4)

      4 - CERUS CORP (0001020214) (Issuer)

      5/14/24 6:30:46 PM ET
      $CERS
      EDP Services
      Technology
    • Nachtsheim Jami K bought $3,578 worth of shares (2,000 units at $1.79), increasing direct ownership by 2% to 108,362 units (SEC Form 4)

      4 - CERUS CORP (0001020214) (Issuer)

      5/13/24 5:09:19 PM ET
      $CERS
      EDP Services
      Technology

    $CERS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Craig Hallum initiated coverage on Cerus with a new price target

      Craig Hallum initiated coverage of Cerus with a rating of Buy and set a new price target of $5.00

      4/12/24 8:00:30 AM ET
      $CERS
      EDP Services
      Technology
    • Cerus downgraded by BTIG Research

      BTIG Research downgraded Cerus from Buy to Neutral

      1/20/23 10:02:56 AM ET
      $CERS
      EDP Services
      Technology
    • Cerus downgraded by Stephens with a new price target

      Stephens downgraded Cerus from Overweight to Equal-Weight and set a new price target of $3.75

      1/17/23 7:57:35 AM ET
      $CERS
      EDP Services
      Technology

    $CERS
    Leadership Updates

    Live Leadership Updates

    See more

    $CERS
    SEC Filings

    See more

    $CERS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Cerus Corporation Announces Appointment of Dean Gregory to Board of Directors

      Cerus Corporation (NASDAQ:CERS) today announced the appointment of Dean Gregory to its Board of Directors. Mr. Gregory has a 30+-year career as a leader in the global blood transfusion and cell therapy industry, with broad experience across commercialization, product development, supply chain and manufacturing. For the last decade, Mr. Gregory served as President, Global Commercial Operations, Med Tech for Fresenius Kabi, the role from which he retired earlier this year. "We are very pleased to welcome Mr. Gregory to Cerus' Board of Directors," said Daniel Swisher, Chair of the Board. "Mr. Gregory brings a wealth of experience and expertise across the global transfusion medicine market, h

      7/2/24 4:00:00 PM ET
      $CERS
      EDP Services
      Technology
    • Cerus Corporation Announces the Appointment of Alicia Goodman as New Chief Human Resources Officer

      Cerus Corporation (NASDAQ:CERS) announced today that Alicia Goodman has been appointed to the role of Chief Human Resources Officer (CHRO). In this role, she will focus on sustaining and evolving the talent and organizational structure to support the future of the business as the leader in safeguarding the global blood supply. Ms. Goodman will also serve as a member of the Company's Executive Leadership Team. "We are excited to welcome Alicia to the Cerus team," said William "Obi" Greenman, Cerus' president and chief executive officer. "As we advance on key global commercial and pipeline initiatives, our talent, leadership and organization structure across all levels of the organization w

      9/27/23 8:30:00 AM ET
      $CERS
      EDP Services
      Technology
    • Cerus Corporation Announces Appointment of Hua Shan, MD, PhD to Board of Directors

      Cerus Corporation (NASDAQ:CERS) today announced the appointment of Hua Shan, MD, PhD, Professor of Pathology and Medical Director, Transfusion Medicine Service at Stanford Medical Center to its Board of Directors. "We are pleased to welcome Dr. Shan to Cerus' Board of Directors," said Daniel Swisher, Chair of the Board. "Dr. Shan is an accomplished, leading voice in the transfusion community, with more than twenty-five years of experience in the field, bringing a wealth of knowledge and insight to our Board. In addition, Dr. Shan has extensive experience with international blood bank practices including the Chinese transfusion market. We expect to benefit from Dr. Shan's expertise as we co

      7/5/22 5:00:00 PM ET
      $CERS
      EDP Services
      Technology
    • SEC Form SD filed by Cerus Corporation

      SD - CERUS CORP (0001020214) (Filer)

      5/30/25 4:01:40 PM ET
      $CERS
      EDP Services
      Technology
    • SEC Form DEFA14A filed by Cerus Corporation

      DEFA14A - CERUS CORP (0001020214) (Filer)

      5/23/25 12:01:02 PM ET
      $CERS
      EDP Services
      Technology
    • SEC Form 10-Q filed by Cerus Corporation

      10-Q - CERUS CORP (0001020214) (Filer)

      5/1/25 5:06:25 PM ET
      $CERS
      EDP Services
      Technology
    • Amendment: SEC Form SC 13G/A filed by Cerus Corporation

      SC 13G/A - CERUS CORP (0001020214) (Subject)

      11/12/24 9:53:11 AM ET
      $CERS
      EDP Services
      Technology
    • SEC Form SC 13G/A filed by Cerus Corporation (Amendment)

      SC 13G/A - CERUS CORP (0001020214) (Subject)

      2/14/24 4:21:51 PM ET
      $CERS
      EDP Services
      Technology
    • SEC Form SC 13G/A filed by Cerus Corporation (Amendment)

      SC 13G/A - CERUS CORP (0001020214) (Subject)

      2/13/24 5:01:03 PM ET
      $CERS
      EDP Services
      Technology